Download Composition ENG

CEPHALON
International biopharmaceutical
research company
| WORLDWIDE SITES
| KEY DATES
1987 Creation by Frank Baldino Jr., Ph.D.
1991 NASDAQ IPO (CEPH)
1994 MODIODAL® (modafinil) launch in France, first
in a new class of wakefulness promoting agents for
treating disabling excessive daytime sleepiness disorders
1998 PROVIGIL® ( modafinil) launch in the UK/Ireland
1999 PROVIGIL® launch in the US
2000 Acquisition of ACTIQ® (fentany citrate) for the treatment
of BreakThrough cancer Pain (BTcP)
2001 Acquisition of Louis Lafon Laboratories in France
2004 Acquisition of CIMA Labs, Inc., a leader in drug delivery
technologies
2005 Acquisitions:
| KEY FIGURES
3000 people worldwide of which 300 in R&D and 900 in Europe
Over 30 drugs marketed in more than 50 countries
Revenues: $1.97 billion in 2008
R&D investments: 18 % of 2008 revenues
Cephalon is listed on the NASDAQ (CEPH),
since 1991, and was recently added to the
NASDAQ-100 Index, which includes 100 of
the largest high-tech securities.
▬ TREANDA® (bendamustine) for haematological malignancies in the United States only
▬ TRISENOX® (arsenic trioxide) for Acute
Promyelocytic Leukaemia (APL)
▬ Zeneus Pharma Ltd, a European company
specialised in oncology
2006 ▬ Creation of a Joint Venture in Asia
▬ Launch of MODIODAL® (modafinil) in Japan
2007 Acquisition of AMRIX® (cyclobenzaprine hydrochloride
extended-release capsules) a myorelaxant for relief of
muscle spasm, in the United States only
2008 TREANDA® (bendamustine hydrochloride) launch
For the second time, Cephalon was
highlighted on the Fortune 1000 annual
ranking of America’s largest corporations.
Cephalon is one of only 19 companies in the
pharmaceutical sector to make FORTUNE
magazine’s list.
The World Economic Forum in Davos inducted
Cephalon into its “Community of Global Growth
Companies” in 2006 and thus highlighted
Cephalon as one of the next generation of
global multinational companies.
Added in 2008 to the Standard & Poor’s 500
Index considered as the best single gauge of
the US equities market
in the US in:
- Chronic Lymphocytic Leukaemia (CLL)
- Relapsed Indolent Non-Hodgkin’s Lymphoma (NHL)
2009 ▬ EFFENTORA® pan European launch in
BreakThrough cancer Pain
▬ Acquisitions:
- Ception Therapeutics, Inc., whose lead product,
reslizumab, is a humanised monoclonal antibody
against interleukin-5
- Lupuzor™, for the treatment of systemic lupus
erythematosus
- Arana Therapeutics, an Australian biopharmaceutical
company on next generation antibodies in
inflammatory diseases and cancer
▬ NUVIGIL® (armodafinil) launch in the US
| EUROPEAN SITES AND MORE
Over the past 8 years, Cephalon has invested close to
$1 billion to strengthen its European infrastructure
In addition to its direct presence
in 19 European countries, Cephalon
has partnerships in nearly 50 countries
within Europe, the Middle East and Africa
| Key Medications in Europe, Middle-East and Africa
Central Nervous System
Pain
PROVIGIL®/MODIODAL®/VIGIL®/MODASOMIL® (modafinil): a wake
promoting agent for disabling excessive daytime sleepiness disorders
related to narcolepsy, OSA/HS (Obstructive Sleep Apnoea/Hypopnea
Syndrome) and SWSD (Shift Work Sleep Disorders)
GABITRIL® (tiagabine): an antiepileptic drug used in adjunct therapy
for treatment of partial seizures
OTRASEL®/ZELAPAR®/XILOPAR® (selegiline freeze-dried tablets):
for Parkinson’s disease
Breakthrough Cancer Pain (BTCP) in adult patients who are already
receiving maintenance opioid therapy for their persistent pain
- ACTIQ® (oral transmucosal fentanyl citrate): using a transmucosal
delivery system on a plastic handle
- EFFENTORA® (fentanyl buccal tablet): a new formulation using
OraVescent® technology which enhances the rate and extent of fentanyl absorption through the buccal mucosa
Oncology, Haematology & associated infections
Primary Care
MYOCET® (liposomal doxorubicin): indicated in combination with
cyclophosphamide for first-line treatment of metastatic breast cancer
TRISENOX® (arsenic trioxide): for the treatment of relapsed or refractory Acute Promyelocytic Leukaemia (APL) a specific form of Acute
Myeloid Leukeamia (AML)
TARGRETIN® (bexarotene): a treatment for cutaneous T-cell lymphoma
ABELCET® (amphotericin B lipid complex): for the treatment of invasive fungal infections in patients who are refractory or intolerant of a
conventional amphotericin B therapy, mostly prescribed to patients
suffering from cancer
SPASFON®/SPASFON-LYOC®(phloroglucinol/trimethylphloroglucinol):
an antispasmodic indicated in abdominal pain for various diseases
NAXY®/MONONAXY® (clarythromycin): a broad spectrum antibiotic
PARALYOC® (paracetamol): an analgesic-antipyretic for relief of mild to
moderate pain and febrile states
PROXALYOC® (piroxicam): a non steroidal anti-inflammatory medication
treating arthroses and arthritis
LOPERAMIDE-LYOC® (loperamide): for acute and chronic diarrheas
Products listed above are not necessarily marketed in all European, Middle East and African countries nor in all indications
Updated-January 2010
Contact: Marie-Dominique de La Salle/ Communications & Public Affairs
Tel. +33 1 49 81 82 48 – [email protected]